{
    "organizations": [],
    "uuid": "0e0866fc65c4e1ab0da369058d0a2b536708a303",
    "author": "",
    "url": "https://www.reuters.com/article/brief-neptune-tetra-bio-pharma-enter-co/brief-neptune-tetra-bio-pharma-enter-co-development-agreement-for-purified-cannabinoid-oil-based-products-targeting-pain-inflammation-idUSFWN1Q211R",
    "ord_in_thread": 0,
    "title": "BRIEF-Neptune, Tetra Bio-Pharma Enter Co-Development Agreement For Purified Cannabinoid Oil-Based Products Targeting Pain, Inflammation",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": " 11 PM / in 7 minutes BRIEF-Neptune, Tetra Bio-Pharma Enter Co-Development Agreement For Purified Cannabinoid Oil-Based Products Targeting Pain, Inflammation Reuters Staff 1 Min Read \nFeb 12 (Reuters) - Tetra Bio Pharma Inc: \n* NEPTUNE AND TETRA BIO-PHARMA ENTER CO-DEVELOPMENT AGREEMENT FOR PURIFIED CANNABINOID OIL-BASED PRODUCTS TARGETING PAIN AND INFLAMMATION Source text for Eikon:  ",
    "published": "2018-02-12T15:10:00.000+02:00",
    "crawled": "2018-02-12T15:26:27.009+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "pm",
        "minute",
        "tetra",
        "enter",
        "agreement",
        "purified",
        "cannabinoid",
        "product",
        "targeting",
        "pain",
        "inflammation",
        "reuters",
        "staff",
        "min",
        "read",
        "feb",
        "reuters",
        "tetra",
        "bio",
        "pharma",
        "inc",
        "neptune",
        "tetra",
        "enter",
        "agreement",
        "purified",
        "cannabinoid",
        "product",
        "targeting",
        "pain",
        "inflammation",
        "source",
        "text",
        "eikon"
    ]
}